These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1478 related articles for article (PubMed ID: 12717301)
1. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
2. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Kuschel B; Lux MP; Goecke TO; Beckmann MW Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253 [TBL] [Abstract][Full Text] [Related]
3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
5. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836 [TBL] [Abstract][Full Text] [Related]
6. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related]
7. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246 [TBL] [Abstract][Full Text] [Related]
10. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region. Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938 [TBL] [Abstract][Full Text] [Related]
11. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. Woodward AM; Davis TA; Silva AG; Kirk JA; Leary JA; J Med Genet; 2005 May; 42(5):e31. PubMed ID: 15863663 [TBL] [Abstract][Full Text] [Related]
12. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]. Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051 [TBL] [Abstract][Full Text] [Related]
14. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P; Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744 [TBL] [Abstract][Full Text] [Related]
15. [Inherited breast and ovarian cancers]. Gerdes AM; Ejlertsen B Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422 [TBL] [Abstract][Full Text] [Related]
16. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429 [TBL] [Abstract][Full Text] [Related]
17. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170 [TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
19. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860 [TBL] [Abstract][Full Text] [Related]
20. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]